XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
XOMA Royalty Corporation (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
XOMA Royalty Corporation (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's leadership team, including CEO Owen Hughes and CIO Brad Sitko, will deliver a company update presentation on Monday, September 8, 2025, at 9:00 AM ET.
Investors can access the presentation through a webcast link or via the investor relations section of XOMA's website at www.xoma.com.
Details
News Market Reaction – XOMA
On Sep 3, the day this news came out, XOMA closed 0.29% above the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference.
Mr. Hughes and Mr. Sitko will present on Monday, September 8, 2025 at 9:00 AM ET. The webcast for the presentation can be accessed by visiting https://bit.ly/4mjFgkY. XOMA Royalty’s presentation can be also accessed by visiting the investor relations section of the Company’s website at www.xoma.com.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
| XOMA Investor Contact | XOMA Media Contact |
| Juliane Snowden | Kathy Vincent |
| XOMA Royalty | KV Consulting & Management |
| +1 646-438-9754 | kathy@kathyvincent.com |
| juliane.snowden@xoma.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.